CY 9652

Drug Profile

CY 9652

Latest Information Update: 26 Apr 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Epimmune
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 26 Apr 1999 Discontinued-Preclinical for Asthma in USA (Inhalation)
  • 26 Apr 1999 Discontinued-Preclinical for Multiple sclerosis in USA (Unknown route)
  • 26 Apr 1999 Discontinued-Preclinical for Rheumatoid arthritis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top